# Study on Analgesia of GIC-1001 & GIC-1002 on Visceral Pain, Rectal Sensory Threshold Using the Barostat Method

> **NCT02276768** · PHASE1 · COMPLETED · sponsor: **gicare Pharma Inc.** · enrollment: 90 (actual)

## Conditions studied

- Pain
- Cancer
- Colonic Disease

## Interventions

- **DRUG:** GIC-1001 375 mg TID
- **DRUG:** GIC-1001 500 mg TID
- **DRUG:** GIC-1002 345 mg TID (equimolar to GIC-1001 375 mg TID)
- **DRUG:** GIC-1002 460 mg (equimolar to GIC-1001 500 mg)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02276768
- **Lead sponsor:** gicare Pharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2016-08-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02276768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02276768, "Study on Analgesia of GIC-1001 & GIC-1002 on Visceral Pain, Rectal Sensory Threshold Using the Barostat Method". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02276768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*